Treatment of renal allograft acute rejection with methylprednisolone

Effect of fixed dose versus dose per body mass index

Viken Douzdjian, James C. Rice, Kristene Gugliuzza, Jay C. Fisch, Richard W. Carson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Considerable interpatient variability in steroid pharmacokinetics has been observed in renal transplant recipients. The purpose of this retrospective study is to evaluate the relationship between the dose of methylprednisolone (MP) used to treat acute rejection (AR) after renal transplantation and the response to treatment. 117 first AR episodes from 408 renal transplants were reviewed. The dose of MP used to treat AR was < 45 mg/kg/m2 in 60 patients and ≤ 45 mg/kg/m2 in 57 patients. The correlation between fixed dose (< 1.25 vs. ≤ 1.25 g) and dose based on BMI was evaluated by simple linear regression analysis (r2 = 0.78, p < 0.0005). Response to treatment was as follows: MP successful (Group 1, n = 80); MP failed, OKT3 successful (Group 2, n = 17); MP and OKT3 failed (Group 3, n = 3) and MP failed, no further treatment (n = 17). No relationship was observed between the dose of MP, whether fixed or based on BMI, and (1) response to treatment of the first AR, (2) incidence of a second AR and (3) response to subsequent treatment with OKT3. Actuarial graft survival was higher in Group 1 compared to Group 2 (p < 0.0005), lower in Black recipients (p = 0.02) and higher when ≤ 45 mg/kg/m2 of MP was used to treat AR (p = 0.06). In conclusion, no relationship between the dose of MP, whether fixed or based on BMI, and the response to treatment of AR was observed. MP dosage based on BMI may be a reasonable alternative to a fixed-dose regimen with the advantage of limiting steroid exposure and the consequent side-effects.

Original languageEnglish (US)
Pages (from-to)310-315
Number of pages6
JournalClinical Transplantation
Volume10
Issue number3
StatePublished - 1996

Fingerprint

Methylprednisolone
Allografts
Body Mass Index
Kidney
Muromonab-CD3
Therapeutics
Steroids
Graft Survival
Kidney Transplantation
Linear Models
Retrospective Studies
Pharmacokinetics
Regression Analysis
Transplants
Incidence

Keywords

  • Kidney transplant
  • Methylprednisolone
  • Rejection

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Treatment of renal allograft acute rejection with methylprednisolone : Effect of fixed dose versus dose per body mass index. / Douzdjian, Viken; Rice, James C.; Gugliuzza, Kristene; Fisch, Jay C.; Carson, Richard W.

In: Clinical Transplantation, Vol. 10, No. 3, 1996, p. 310-315.

Research output: Contribution to journalArticle

Douzdjian, Viken ; Rice, James C. ; Gugliuzza, Kristene ; Fisch, Jay C. ; Carson, Richard W. / Treatment of renal allograft acute rejection with methylprednisolone : Effect of fixed dose versus dose per body mass index. In: Clinical Transplantation. 1996 ; Vol. 10, No. 3. pp. 310-315.
@article{03ef87a2373449ec9a08b69ebce367d1,
title = "Treatment of renal allograft acute rejection with methylprednisolone: Effect of fixed dose versus dose per body mass index",
abstract = "Considerable interpatient variability in steroid pharmacokinetics has been observed in renal transplant recipients. The purpose of this retrospective study is to evaluate the relationship between the dose of methylprednisolone (MP) used to treat acute rejection (AR) after renal transplantation and the response to treatment. 117 first AR episodes from 408 renal transplants were reviewed. The dose of MP used to treat AR was < 45 mg/kg/m2 in 60 patients and ≤ 45 mg/kg/m2 in 57 patients. The correlation between fixed dose (< 1.25 vs. ≤ 1.25 g) and dose based on BMI was evaluated by simple linear regression analysis (r2 = 0.78, p < 0.0005). Response to treatment was as follows: MP successful (Group 1, n = 80); MP failed, OKT3 successful (Group 2, n = 17); MP and OKT3 failed (Group 3, n = 3) and MP failed, no further treatment (n = 17). No relationship was observed between the dose of MP, whether fixed or based on BMI, and (1) response to treatment of the first AR, (2) incidence of a second AR and (3) response to subsequent treatment with OKT3. Actuarial graft survival was higher in Group 1 compared to Group 2 (p < 0.0005), lower in Black recipients (p = 0.02) and higher when ≤ 45 mg/kg/m2 of MP was used to treat AR (p = 0.06). In conclusion, no relationship between the dose of MP, whether fixed or based on BMI, and the response to treatment of AR was observed. MP dosage based on BMI may be a reasonable alternative to a fixed-dose regimen with the advantage of limiting steroid exposure and the consequent side-effects.",
keywords = "Kidney transplant, Methylprednisolone, Rejection",
author = "Viken Douzdjian and Rice, {James C.} and Kristene Gugliuzza and Fisch, {Jay C.} and Carson, {Richard W.}",
year = "1996",
language = "English (US)",
volume = "10",
pages = "310--315",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Treatment of renal allograft acute rejection with methylprednisolone

T2 - Effect of fixed dose versus dose per body mass index

AU - Douzdjian, Viken

AU - Rice, James C.

AU - Gugliuzza, Kristene

AU - Fisch, Jay C.

AU - Carson, Richard W.

PY - 1996

Y1 - 1996

N2 - Considerable interpatient variability in steroid pharmacokinetics has been observed in renal transplant recipients. The purpose of this retrospective study is to evaluate the relationship between the dose of methylprednisolone (MP) used to treat acute rejection (AR) after renal transplantation and the response to treatment. 117 first AR episodes from 408 renal transplants were reviewed. The dose of MP used to treat AR was < 45 mg/kg/m2 in 60 patients and ≤ 45 mg/kg/m2 in 57 patients. The correlation between fixed dose (< 1.25 vs. ≤ 1.25 g) and dose based on BMI was evaluated by simple linear regression analysis (r2 = 0.78, p < 0.0005). Response to treatment was as follows: MP successful (Group 1, n = 80); MP failed, OKT3 successful (Group 2, n = 17); MP and OKT3 failed (Group 3, n = 3) and MP failed, no further treatment (n = 17). No relationship was observed between the dose of MP, whether fixed or based on BMI, and (1) response to treatment of the first AR, (2) incidence of a second AR and (3) response to subsequent treatment with OKT3. Actuarial graft survival was higher in Group 1 compared to Group 2 (p < 0.0005), lower in Black recipients (p = 0.02) and higher when ≤ 45 mg/kg/m2 of MP was used to treat AR (p = 0.06). In conclusion, no relationship between the dose of MP, whether fixed or based on BMI, and the response to treatment of AR was observed. MP dosage based on BMI may be a reasonable alternative to a fixed-dose regimen with the advantage of limiting steroid exposure and the consequent side-effects.

AB - Considerable interpatient variability in steroid pharmacokinetics has been observed in renal transplant recipients. The purpose of this retrospective study is to evaluate the relationship between the dose of methylprednisolone (MP) used to treat acute rejection (AR) after renal transplantation and the response to treatment. 117 first AR episodes from 408 renal transplants were reviewed. The dose of MP used to treat AR was < 45 mg/kg/m2 in 60 patients and ≤ 45 mg/kg/m2 in 57 patients. The correlation between fixed dose (< 1.25 vs. ≤ 1.25 g) and dose based on BMI was evaluated by simple linear regression analysis (r2 = 0.78, p < 0.0005). Response to treatment was as follows: MP successful (Group 1, n = 80); MP failed, OKT3 successful (Group 2, n = 17); MP and OKT3 failed (Group 3, n = 3) and MP failed, no further treatment (n = 17). No relationship was observed between the dose of MP, whether fixed or based on BMI, and (1) response to treatment of the first AR, (2) incidence of a second AR and (3) response to subsequent treatment with OKT3. Actuarial graft survival was higher in Group 1 compared to Group 2 (p < 0.0005), lower in Black recipients (p = 0.02) and higher when ≤ 45 mg/kg/m2 of MP was used to treat AR (p = 0.06). In conclusion, no relationship between the dose of MP, whether fixed or based on BMI, and the response to treatment of AR was observed. MP dosage based on BMI may be a reasonable alternative to a fixed-dose regimen with the advantage of limiting steroid exposure and the consequent side-effects.

KW - Kidney transplant

KW - Methylprednisolone

KW - Rejection

UR - http://www.scopus.com/inward/record.url?scp=0030018380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030018380&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 310

EP - 315

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 3

ER -